Safety and Efficacy of Sildenafil Citrate for the Treatment of Female Sexual Arousal Disorder: A Double-Blind, Placebo Controlled Study
One hundred women (Figure) of
- The legality of women using sildenafil varies by country and local regulations.
- Lifestyle modifications can complement medication for better sexual health outcomes.
- Women with diabetes may have different responses to sildenafil therapy.
- The stigma surrounding female sexual dysfunction can hinder treatment seeking.
- Advances in research are aimed at developing female-specific ED medications.
- Open discussions with physicians are essential for safe and effective treatments.
the 145 screened met eligibility requirements.
| Trend | Description | Potential Impact |
|---|---|---|
| Development of women-specific formulations | Customized doses and delivery methods | Improved safety and efficacy |
| Combination therapies | Sildenafil combined with other agents | Potentially enhanced outcomes |
| Non-oral delivery systems | Topicals, patches, or injectables | Increased convenience and quicker onset |
| Personalized medicine approaches | Genetic testing to optimize treatment | Higher success rates with fewer side effects |
| Increased clinical trials in women | More robust evidence for approval | Better guideline development |
Among the most frequent causes for exclusion
- Sildenafil is a medication primarily used to treat erectile dysfunction in men.
- Women sildenafil is an off-label use aimed at improving female sexual arousal.
- Clinical trials are ongoing to assess efficacy of sildenafil for women.
- Side effects of sildenafil may include headaches, flushing, and nasal congestion.
- Women may experience increased blood flow and libido with sildenafil.
- Proper dosage and medical consultation are essential before use.
were ineligible protocol criteria (ie, lack of
- Some women seek sildenafil for increasing genital blood flow and sensation.
- The placebo effect can influence perceived benefits in women using sildenafil.
- Women with cardiovascular risk should avoid sildenafil unless approved by a doctor.
- Topical or alternative therapies might be considered alongside or instead of sildenafil.
- Scientific consensus on sildenafil’s safety for women remains under development.
- Proper dosing and medical oversight are key to minimizing risks.
acceptable and verifiable form of contraception, perimenopausal
- Sildenafil works by relaxing blood vessels, increasing blood flow to genital areas.
- Female sexual arousal disorder may potentially be treated with sildenafil.
- Research shows mixed results regarding sildenafil's effectiveness in women.
- Sildenafil is not approved by the FDA specifically for women’s sexual problems.
- Possible risks for women include headaches and low blood pressure.
- Always consult a healthcare provider before trying sildenafil for women.
with irregular cycles or amenorrhea, non-SRI sexual dysfunction
What should I do in case of overdose?
Independent samples t tests compared baseline patient characteristics and Clinical Global Impression sexual function scores between the study groups at end point. The χ2 analyses were used to evaluate group differences in categorical measures. Analyses were based on intent-to-treat with the last-observation-carried-forward analyses performed on all variables and included data from all protocol-treated patients. All randomized patients received and took at least 1 dose of study trial medication, had at least 1 efficacy assessment, and were included regardless of protocol deviations or whether they completed the study. The final analysis included women who completed the trial, but for the women who did not complete the trial, their baseline value was carried forward in separate analyses.
Can Viagra make a woman wet?
The change in sexual functioning by Clinical Global Impression sexual function score and all other questionnaires from baseline to each patient's own end point were the dependent measures of efficacy. A repeated measures analysis of variance was used to determine differences between placebo and sildenafil in the change from baseline to end point for the measures of efficacy and depression severity (time × group interaction). In sildenafil online ireland addition, exact nonparametric methods were applied to the efficacy measures to substantiate results that rely on distributional assumptions. Findings were also confirmed with analysis of covariance and Wilcoxon rank sum tests for primary analyses. All statistical tests were 2-sided, and all hypotheses were evaluated at the 5% significance level. augmentation, switching antidepressant agent, other treatments for
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Soft Tabs | 100mg | 272 + 12 Pills | 593.42€ 565.16€ | |
| Viagra Generic | 150mg | 30 + 2 Pills | 72.32€ 68.88€ | |
| Viagra Generic | 50mg | 60 + 4 Pills | 83.93€ 79.93€ | |
| Viagra Generic | 100mg | 360 + 10 Pills | 330.21€ 314.49€ | |
| Kamagra Oral Jelly | 100mg | 10 Sachets | 54.55€ 51.95€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Viagra Generic | 200mg | 180 + 10 Pills | 277.56€ 264.34€ | |
| Kamagra Oral Jelly | 100mg | 63 + 7 Sachets | 224.18€ 213.50€ | |
| Kamagra | 100mg | 360 + 6 Pills | 839.95€ 799.95€ | |
| Viagra Generic | 150mg | 20 Pills | 55.02€ 52.40€ | |
| Kamagra Soft Tabs | 100mg | 32 Pills | 120.11€ 114.39€ | |
| Viagra Generic | 150mg | 10 Pills | 36.73€ 34.98€ | |
| Viagra Generic | 25mg | 90 + 6 Pills | 105.03€ 100.03€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ |
sexual dysfunction), and other miscellaneous reasons (partner
Rights and permissions
The F test of the overall hypothesis test was first conducted before multiple comparisons analyses. Sample-size calculations were based on detecting a difference in full response rates at 8 weeks, assuming a response rate of 70% for sildenafil and 35% for placebo. Thus, a sample size of 82 evaluable patients (41 per group) was expected to detect a significant difference with 90% power for a type I error rate of α = .05 between sildenafil and placebo (2-sided). Assuming 20% attrition, 100 patients were planned to be randomized and 98 patients were entered. The sample size determination assumed no interactions of treatment with site or antidepressant.
Comparison table
The primary analysis was according to assignment at randomization. In addition to determination of this narrow measure of efficacy based on all randomized patients and imputing the worst rank scores for early exclusions due to protocol violations before and without taking the trial drug, there was a general efficacy analysis for all protocol-treated patients and all trial completers. Adjusted means (SDs) were determined and reported. Where applicable, 95% confidence intervals (CIs) are provided. Analyses were performed with SAS version 9.1.3 (SAS Institute Inc, Cary, North Carolina). issues, abnormal Papanicolaou test results, medical comorbidity,
| Country | Legal Status | Prescription Required | Notes |
|---|---|---|---|
| USA | Approved for certain uses | Yes | Off-label for women often not approved |
| UK | Prescription-only | Yes | Approved for male ED; off-label use in women |
| Canada | Restricted use | Yes | Prescription required; variable by province |
| Australia | Prescription-only | Yes | Limited clinical guidelines for women |
excessive alcohol use, or relationship or partner problems).
OUR PRE-FULFILLMENT PRESCRIPTION PERIOD HAS BEGUN.
Using SPSS version 10 (SPSS Inc, Chicago, Illinois), an unrestricted, computer-generated randomization schedule was developed by the study statistician (S.P.) and given to the independent pharmacy. The randomization assigned 49 patients to receive active sildenafil and 49 to receive identical placebo. The only restriction to this randomization was that the groups be of equal size. The largest difference in numbers assigned to the 2 groups at any point in the trial was 4 (excludes completions). At baseline, patients were allocated to the next available number that randomly assigned them to receive sildenafil or matching placebo (50-mg starting dose).
Raynaud's phenomenon
Medications were sealed in sequentially numbered identical containers according to allocation sequence, and all study personnel and participants were blinded to treatment assignment for the duration of the study. Patients were instructed to take 1 tablet of trial medication approximately 1 to 2 hours before anticipated sexual activity, not more than once daily over the 8-week trial period and were required to make at least 1 attempt but were asked to try to make at least 2 attempts at sexual activity per week. The dose of study drug could be adjusted from 1 (50 mg) to 2 (100 mg) tablets based on investigator judgment of efficacy and tolerability, including the recording of the findings that resulted in any study drug dosage change and adverse events. Patients were given diaries with instructions for recording trial medication use and sexual activity. Sildenafil and placebo were provided by Pfizer Inc, New York, New York.